Evidence map›Paper›PMID 31831621›Full record

ArticleThe Journal of biological chemistry2020

Disruption of hepatic small heterodimer partner induces dissociation of steatosis and inflammation in experimental nonalcoholic steatohepatitis.

Nancy Magee, An Zou, Priyanka Ghosh, Forkan Ahamed, Don Delker, Yuxia Zhang

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Targeting the Liver Serine Protease TMPRSS6 Ameliorates Steatosis and Attenuates Fibrosis in Experimental MASLD.Liver international : official journal of the International Association for the Study of the Liver · 2025
    Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Nancy MageeDepartment of Pharmacology, Toxicology, and Therapeutics, University of Kansas Medical Center, Kansas City, Kansas 66160.
An ZouDepartment of Pharmacology, Toxicology, and Therapeutics, University of Kansas Medical Center, Kansas City, Kansas 66160.
Priyanka GhoshDepartment of Pharmacology, Toxicology, and Therapeutics, University of Kansas Medical Center, Kansas City, Kansas 66160.
Forkan AhamedDepartment of Pharmacology, Toxicology, and Therapeutics, University of Kansas Medical Center, Kansas City, Kansas 66160.ORCID 0000-0003-1433-4573
Don DelkerDepartment of Medicine, University of Utah School of Medicine, Salt Lake City, Utah 84108.
Yuxia ZhangDepartment of Pharmacology, Toxicology, and Therapeutics, University of Kansas Medical Center, Kansas City, Kansas 66160 lzhang5@kumc.edu.ORCID 0000-0001-9951-3583
University of Kansas Medical Center · USUniversity of Utah · US

Funding

Mentoring CoreP20GM103418 · NIGMS · UNIVERSITY OF KANSAS MEDICAL CENTER · PI John A Stanford · 2012 to 2026
$63.0M
RADx-UP: Improving the Response of Local Urban and Rural Communities to Disparities in Covid-19 TestingUL1TR002366 · NCATS · UNIVERSITY OF KANSAS MEDICAL CENTER · PI Mario Castro, JAMES STEVEN LEEDER · 2017 to 2026
$44.3M
THE ROLE OF HUMAN PXR IN ANTI-TUBERCULOSIS DRUG-INDUCED LIVER INJURYP20RR021940 · NCRR · UNIVERSITY OF KANSAS MEDICAL CENTER · PI KRISHNAMURTHY, PARTHA C · 2006 to 2011
$12.1M
Nuclear Receptors in Liver Health and DiseaseP20GM103549 · NIGMS · UNIVERSITY OF KANSAS MEDICAL CENTER · PI JAESCHKE, HARTMUT W. · 2012 to 2015
$8.1M
Pilot Grants ProgramP30GM118247 · NIGMS · UNIVERSITY OF KANSAS MEDICAL CENTER · PI WEINMAN, STEVEN A · 2016 to 2020
$5.5M
TRAINING PROGRAM IN ENVIRONMENTAL TOXICOLOGYT32ES007079 · NIEHS · UNIVERSITY OF KANSAS MEDICAL CENTER · PI HAGENBUCH, BRUNO · 1985 to 2015
$4.1M
RNA-binding protein HuR in liver pathophysiology and carcinogenesisR01DK119131 · NIDDK · UNIVERSITY OF KANSAS MEDICAL CENTER · PI ZHANG, YUXIA · 2019 to 2023
$1.8M
Metabolic reprogramming in liver cancer cells by a novel tumor suppressorK22CA184146 · NCI · UNIVERSITY OF KANSAS MEDICAL CENTER · PI ZHANG, YUXIA · 2014 to 2016
$303k
NCATS NIH HHS UL1 TR002366NCI NIH HHS K22 CA184146NCRR NIH HHS P20 RR021940NIDDK NIH HHS R01 DK119131NIEHS NIH HHS T32 ES007079NIGMS NIH HHS P20 GM103418NIGMS NIH HHS P20 GM103549NIGMS NIH HHS P30 GM118247
6 · The paper itself

Abstract

Nonalcoholic steatohepatitis (NASH) is a leading cause of chronic liver disease worldwide and is characterized by steatosis, inflammation, and fibrosis. The molecular mechanisms underlying NASH development remain obscure. The nuclear receptor small heterodimer partner (

Indexed as

AnimalsDiet, High-FatDisease ProgressionGene DeletionGene OntologyHepatocytesInflammationLiverLiver CirrhosisMice, Inbred C57BLMice, KnockoutNF-kappa BNon-alcoholic Fatty Liver DiseasePPAR gammaReceptors, Cytoplasmic and NuclearSignal TransductionNF-kappa Bnuclear receptor subfamily 0, group B, member 2PPAR gammaReceptors, Cytoplasmic and Nuclearfatty liver diseasefibrosisinflammationlipid metabolismlivernonalcoholic steatohepatitis (NASH)nuclear receptorRNA sequencingsmall heterodimer partner (SHP)steatosis

Identifiers

PMID31831621
PMCPMC6983844
OpenAlexW2995641082

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.